Onconic Therapeutics to Unveil Next-Generation Obesity Drug Candidate at Conference for First Time

[Financial News] Onconic Therapeutics is set to unveil for the first time a next-generation drug candidate it is developing, following Zastaprazan, a treatment for gastroesophageal reflux disease, and the anticancer drug Nesuparib. As the global obesity-treatment market expands rapidly, the company appears to be stepping up efforts to develop new obesity drugs.
Onconic Therapeutics said on the 28th that it will orally present research findings on a new drug candidate at ObesityWeek 2026, a global obesity-focused academic conference scheduled to take place in November in Washington, D.C. The study was selected as a Late-Breaking Abstract by the conference.
Late-Breaking Abstracts are selected from newly released studies ahead of a conference based on factors such as their significance and novelty. An oral presentation is a format in which selected research findings are presented directly at the event.
This presentation marks the first official disclosure by Onconic Therapeutics of a new drug candidate following its existing drugs, Zastaprazan and Nesuparib. However, the company has not disclosed the candidate's name or specific research details and findings because of the conference embargo.
Beginning with this conference, Onconic Therapeutics plans to fully launch research and development of the next-generation drug candidate. The company explained that it has used its proprietary AI-based analysis and screening system to identify the candidate's potential and validate it through research.
Obesity has recently emerged as a major drug-development field in the global pharmaceutical and biotechnology industries. The market is expanding on the growth of GLP-1 obesity treatments, while development of new therapies, joint research among companies and technology transfers are also becoming increasingly active. IQVIA, a pharmaceutical market research firm, forecasts that the global obesity-treatment market will grow from approximately $66 billion in 2025 to approximately $92 billion in 2026.
An Onconic Therapeutics official said, "Following the commercialization of Zastaprazan and the development of Nesuparib, we are introducing for the first time a next-generation drug candidate aimed at becoming a global blockbuster," adding, "Beginning with this presentation, we plan to disclose specific research achievements sequentially and develop the candidate into a global drug."

[email protected] Jung Sang-hee Reporter